ConVerd's first oncolytic vaccinia virus product V01 Obtained Clinical Trial Approval

On March 28, 2023, ConVerd’s first oncolytic vaccinia virus product, hV01, received implicit approval for clinical trials from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). Subsequently, clinical trials will be initiated at centers including Fudan University Shanghai Cancer Center. As the lead clinical site for the Phase I trial of hV01, Fudan University Shanghai Cancer Center obtained approval from its Medical Ethics Committee on March 30, 2023, greenlighting the trial's commencement. 

ConVerd owns the first domestic independent intellectual property rights for oncolytic vaccinia virus technology platform. hV01 is the first-generation product independently developed by ConVerd based on unmet clinical needs in anticancer therapeutics and the biological characteristics of the virus. The construct of hV01 features a double-gene knockout backbone virus engineered with the immunomodulatory factor IL-21, which induces both innate and adaptive immune responses, serving as a marker for follicular helper T cells that bridges the cross-reaction between humoral and cellular immunity.

As the inaugural product of ConVerd’s globally pioneering systemic tumor immunotherapy, hV01 will explore monotherapy and targeted combination strategies for refractory tumors, paving the way for future advancements and breakthroughs in cancer treatment.